Humacyte (HUMA) EBT (2020 - 2026)

Humacyte (HUMA) has reported EBT for 7 consecutive years, with -$28.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 7.99% year-over-year to -$28.9 million in Q2 2026; TTM through Jun 2026 was -$119.6 million, a 0.98% decrease from a year earlier, with the FY2025 full-year figure at -$116.8 million, up 2.32% from the prior year.
• EBT was -$28.9 million for Q2 2026 at Humacyte, up from -$30.9 million in the prior quarter.
• Over five years, EBT peaked at -$19.7 million in Q2 2022 and troughed at -$33.4 million in Q4 2025.
• A 5-year average of -$27.0 million and a median of -$26.8 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT climbed 23.16% in 2022 and slumped 36.74% in 2023, its largest moves.
• Over 5 years, EBT stood at -$21.0 million in 2022, then decreased by 27.13% to -$26.7 million in 2023, then declined by 11.28% to -$29.7 million in 2024, then decreased by 12.37% to -$33.4 million in 2025, then climbed by 13.45% to -$28.9 million in 2026.
• The last three EBT figures came in at -$28.9 million (Q2 2026), -$30.9 million (Q1 2026), and -$33.4 million (Q4 2025), per Business Quant data.